ML348

Research use only, not for human use.

ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM).

ML348, also known as CID 3238952; SID 160654487, is a reversible LYPLA1 inhibitor with an IC50 value of 210 nM. Multiple oncogenes, including HRAS and SRC, require palmitoylation for malignant transformation. Lysophospholipase 1 (LYPLA1) has been identified as a candidate protein palmitoyl thioesterase responsible for HRAS depalmitoylation in mammalian cells.(In Vitro):ML348 (5 μM; 3 hours ) selectively inhibits LYPLA1 in cultured cells.(In Vivo):ML348 (50 mg/kg, i.p., 3 hours) shows potent and selective activity in vivo, inhibits LYPLA1 enzymes in heart, kidney and lung in mice.

ML348 (5 μM; 3 hours ) selectively inhibits LYPLA1 in cultured cells.Cell Viability Assay Cell Line:HEK293T cells, murine T-cells Concentration:5 μM Incubation Time:3 hours Result:Show potent, selective inhibition of LYPLA1.

ML348 (50 mg/kg, i.p., 3 hours) shows potent and selective activity in vivo, inhibits LYPLA1 enzymes in heart, kidney and lung in mice. Animal Model:C57BL6 male mice (3-4 months)Dosage:50 mg/kg Administration:Intraperitoneal injection; 3 hours Result:Potent and selective inhibited LYPLA1 enzymes in heart, kidney and lung in vivo.

ML348 | ML-348 | CID 3238952 | SID 160654487

Angiogenesis

FGFR

LYPLA1

Cancer

——

899713-86-1

415.79

C18H17ClF3N3O3

>98% (HPLC)

DMSO : 25 mg/mL. 60.13 mM;

N1(CCN(CC(=O)Nc2c(ccc(c2)C(F)(F)F)Cl)CC1)C(=O)c1ccco1

N-[2-chloro-5-(trifluoromethyl)phenyl]-4-(2-furanylcarbonyl)-1-piperazineacetamide

(-20℃)

With Ice Pack

≥ 2 years